摘要
目的探讨复方阿嗪米特治疗慢性胆囊炎合并胆结石的临床疗效.方法140例慢性胆囊炎合并胆结石患者,采用动态随机法分为对照组和观察组,各70例.对照组采用常规治疗,观察组采用复方阿嗪米特药物治疗.比较两组患者治疗前后脘腹痞满评分、胆区疼痛评分、纳食减少评分、β内啡肽(β-EP)水平、肿瘤坏死因子-α(TNF-α)水平、血清白细胞介素-6(IL-6)水平,食欲改善起效时间、腹胀起效时间、不良反应发生情况.结果治疗前,观察组患者的脘腹痞满评分、胆区疼痛评分、纳食减少评分分别为(4.46±1.07)、(4.04±0.84)、(3.86±0.68)分,对照组分别为(4.49±1.04)、(4.15±0.78)、(3.91±0.65)分;治疗后,观察组患者的脘腹痞满评分、胆区疼痛评分、纳食减少评分分别为(0.73±0.09)、(1.12±0.14)、(0.87±0.18)分,对照组分别为(2.04±0.23)、(2.41±0.28)、(1.58±0.22)分;两组患者的脘腹痞满评分、胆区疼痛评分、纳食减少评分均低于本组治疗前,且观察组患者的脘腹痞满评分、胆区疼痛评分、纳食减少评分均低于对照组,差异均具有统计学意义(P<0.05).治疗后,观察组患者的β-EP(10.17±2.48)mmol/L、TNF-α(41.27±6.27)ng/L、IL-6(21.24±3.71)ng/L均低于对照组的(16.48±3.71)mmol/L、(50.63±9.45)ng/L、(37.12±4.68)ng/L,差异均具有统计学意义(P<0.05).治疗后,观察组患者的食欲改善起效时间(7.68±1.26)d、腹胀起效时间(5.07±0.45)d均低于对照组的(10.54±1.41)、(7.94±0.86)d,差异均具有统计学意义(P<0.05).观察组患者的不良反应发生率0与对照组的2.86%(2/70)比较,差异无统计学意义(P>0.05).结论采用复方阿嗪米特治疗慢性胆囊炎合并胆结石可有效改善患者预后,提高患者疗效水平,值得推广使用.
Objective To discuss the clinical efficacy of compound azintamide for the treatment of chronic cholecystitis complicated with gallstones. Methods A total of 140 patients with chronic cholecystitis complicated with gallstones were divided by dynamic random method into control group and observation group, with 70 cases in each group. The control group received conventional therapy for treatment, and the observation group received compound azintamide for treatment. Comparison was made on abdominal fullness score, biliary pain score, reduced food intake score,β-endorphin (β-EP) level, tumor necrosis factor-α(TNF-α) level, serum interleukin-6 (IL-6) Level, onset time of appetite improvement, onset time of abdominal distension and occurrence of adverse reactions before and after treatment between the two groups. Results Before treatment, the observation group had abdominal fullness score, biliary pain score and reduced food intake score respectively as (4.46 ± 1.07),(4.04 ± 0.84) and (3.86 ± 0.68) points, which were (4.49 ± 1.04),(4.15 ± 0.78) and (3.91 ± 0.65) points respectively in the control group. After treatment, the observation group had abdominal fullness score, biliary pain score and reduced food intake score respectively as (0.73 ± 0.09),(1.12 ± 0.14) and (0.87 ± 0.18) points, which were (2.04 ± 0.23),(2.41 ± 0.28) and (1.58 ± 0.22) points in the control group. Both groups had lower abdominal fullness score, biliary pain score and reduced food intake score than those before treatment, and the observation group had lower abdominal fullness score, biliary pain score and reduced food intake score than the control group. Their difference was statistically significant (P<0.05). After treatment, the observation group had lower β-EP as (10.17 ± 2.48) mmol/L, TNF-α as (41.27 ± 6.27) ng/L and IL-6 as (21.24 ± 3.71) ng/L than (16.48 ± 3.71) mmol/L,(50.63 ± 9.45) ng/L and (37.12 ± 4.68) ng/L in the control group. Their difference was statistically significant (P<0.05). After treatment, the observ
作者
陈丽斌
余秋强
杜秀珍
CHEN Li-bin;YU Qiu-qiang;DU Xiu-zhen(Dongguan Houjie Hospital, Dongguan 523945, China)
出处
《中国实用医药》
2019年第23期6-8,共3页
China Practical Medicine
关键词
慢性胆囊炎
胆结石
复方阿嗪米特
Chronic cholecystitis
Gallstones
Compound azintamide
